Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer-Reference-Cited by-同舟云学术

Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer

Published:2018-09 Issue: Volume:157 Page:1300-1325
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Zhang Yuan,Lv Handeng,Luo Lu,Xu Yong,Pan Yaqian,Wang Yuewu,Lin Han,Xiong Jianhua,Guo Ping,Zhang Jinsan,Li Xiaokun,Ye Faqing

Funder

National Natural Science Foundation of China

Science and Technology Development of Zhejiang Province

Natural Science Foundation of Zhejiang Province

Xinmiao Talent Project of Zhejiang Province

Zhejiang Provincial Top Key Discipline of Pharmaceutical Sciences

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference25 articles.

1. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat. Rev. Canc.,2007

2. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer;Hirsch;Oncogene,2009

3. Epidermal growth factor receptor inhibitors: a patent review (2010 - present);Li;Expert Opin. Ther. Pat.,2014

4. EGFR mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy;Paez,2004

5. The ErbB/HER family of protein-tyrosine kinases and cancer;Roskoski;Pharmacol. Res.,2014

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-10

2. Structural Perspectives in the Development of Novel EGFR Inhibitors for the Treatment of NSCLC;Mini-Reviews in Medicinal Chemistry;2024-10

3. Targeting cancer using scaffold-hopping approaches: illuminating SAR to improve drug design;Drug Discovery Today;2024-09

4. An Appraisal on Synthetic and Medicinal Aspects of Fused Pyrimidines as Anti Neoplastic Agents;Anti-Cancer Agents in Medicinal Chemistry;2023-03

5. Pyrimidine derivatives as EGFR tyrosine kinase inhibitors in non‐small‐cell lung cancer: A comprehensive review;Chemical Biology & Drug Design;2022-08-02